OMass Therapeutics collects $310M to chase Neurocrine, Vertex in genetic adrenal disorder
An Oxford-based drug developer has raised one of the largest private financings for a UK biotech in recent years as it seeks to follow in the footsteps of Neurocrine and Vertex-acquired Crinetics in an endocrinology ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.